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Abstract
Background: microRNAs are promising candidate breast cancer biomarkers due to their cancer-specific expression
profiles. However, efforts to develop circulating breast cancer biomarkers are challenged by the heterogeneity of
microRNAs in the blood. To overcome this challenge, we aimed to develop a molecular profile of microRNAs
specifically secreted from breast cancer cells. Our first step towards this direction relates to capturing and analyzing
the contents of exosomes, which are small secretory vesicles that selectively encapsulate microRNAs indicative of
their cell of origin. To our knowledge, circulating exosome microRNAs have not been well-evaluated as biomarkers
for breast cancer diagnosis or monitoring.
Methods: Exosomes were collected from the conditioned media of human breast cancer cell lines, mouse plasma
of patient-derived orthotopic xenograft models (PDX), and human plasma samples. Exosomes were verified by
electron microscopy, nanoparticle tracking analysis, and western blot. Cellular and exosome microRNAs from breast
cancer cell lines were profiled by next-generation small RNA sequencing. Plasma exosome microRNA expression
was analyzed by qRT-PCR analysis.
Results: Small RNA sequencing and qRT-PCR analysis showed that several microRNAs are selectively encapsulated
or highly enriched in breast cancer exosomes. Importantly, the selectively enriched exosome microRNA, human
miR-1246, was detected at significantly higher levels in exosomes isolated from PDX mouse plasma, indicating that
tumor exosome microRNAs are released into the circulation and can serve as plasma biomarkers for breast cancer.
This observation was extended to human plasma samples where miR-1246 and miR-21 were detected at significantly
higher levels in the plasma exosomes of 16 patients with breast cancer as compared to the plasma exosomes of
healthy control subjects. Receiver operating characteristic curve analysis indicated that the combination of plasma
exosome miR-1246 and miR-21 is a better indicator of breast cancer than their individual levels.
Conclusions: Our results demonstrate that certain microRNA species, such as miR-21 and miR-1246, are selectively
enriched in human breast cancer exosomes and significantly elevated in the plasma of patients with breast cancer.
These findings indicate a potential new strategy to selectively analyze plasma breast cancer microRNAs indicative of
the presence of breast cancer.
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Background
Breast cancer is the most diagnosed non-skin cancer and
the second leading cause of cancer death in women in
the USA [1]. The 5-year survival rate for women with
early-stage breast cancer is 99 %, which is significantly
higher than in those with advanced-stage invasive breast
cancer (IBC) (24 % among patients with distant metastasis)
[1], thus early detection is still a key to improving breast
cancer outcomes.
Despite significant progress in breast cancer re-
search, reliable biomarkers have yet to be identified.
The current methods for early breast cancer detection,
namely clinical examination and mammography, have
certain limitations in their sensitivity and specificity.
For example, mammography can detect only 70–90 %
of breast lesions [2], with a false-positive rate of up to
31 % [3]. microRNAs are promising candidate bio-
markers due to their cancer-specific expression pro-
files and roles in cancer initiation and progression.
Common microRNA expression changes are observed
in breast cancer tissues at both the pre-invasive and
invasive stage [4, 5] and in serum from patients with
advanced breast cancer [6]. Circulating microRNAs
that are aberrantly expressed in tissues and serum/
plasma have been explored for the purpose of devel-
oping biomarkers for breast cancer [7–9]. However,
this has not been successful, potentially due to the in-
herent heterogeneity of the microRNA populations in
the blood. New strategies in selective detection of
circulating microRNAs are necessary to further the
development of microRNAs as biomarkers for breast
cancer.
Exosomes are endosome-derived nanometer-sized
(50–150 nm) vesicles that are secreted from many cell
types and contain cellular proteins, lipids and micro-
RNAs [10]. Cancer cells secrete exosomes [11, 12], and
the transfer of exosomes from primary tumors to the
circulation has been demonstrated in various model sys-
tems [11, 13]. Furthermore, certain microRNA species
contained in exosomes from cultured breast cancer cells
or ductal lavage samples differ from those secreted from
normal mammary epithelial cells [14], suggesting the po-
tential use of these exosome microRNAs as biomarkers
for the detection of malignant breast disease. However,
to our knowledge, circulating exosome microRNAs have
not been well-evaluated as biomarkers for breast cancer
diagnosis or monitoring. In this study, we characterized
the microRNA content in exosomes derived from breast
cancer cells, and evaluated certain exosome microRNA
species in plasma exosome samples from patient-derived
xenograft (PDX) mice and patients with breast cancer.
The findings from our study support the notion that
plasma exosome microRNAs could serve as biomarkers
for the presence of human breast cancer.
Methods
Cell culture
The human mammary epithelial cell line MCF10A, and
breast cancer cell lines MCF7, ZR-75-1, T47D , BT20,
BT-474, SK-BR-3, and MDA-MB-231 were obtained
from the American Type Culture Collection (Manassas,
VA, USA). MCF10A cells were cultured in DMEM/F12
supplemented with 5 % exosome-depleted horse serum,
20 ng/ml epithelial growth factor, 0.5 mg/ml hydrocorti-
sone, 100 ng/ml cholera toxin, 10 μg/ml insulin, 100 IU/ml
penicillin, and 100 μg/ml streptomycin. MCF7, ZR-75-1,
BT20 and MDA-MB-231 cells were cultivated in DMEM
supplemented with 10 % exosome-depleted fetal bovine
serum (FBS), 100 IU/ml penicillin and 100 μg/ml
streptomycin (Corning/Mediatech, Inc. Manassas, VA,
USA). BT-474 and T47D cells were cultivated in RPMI
medium supplemented with 10 % exosome-depleted
FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin.
SK-BR-3 cells were cultivated in McCoy’s 5A medium
supplemented with 10 % exosome-depleted FBS, 100 IU/ml
penicillin and 100 μg/ml streptomycin. Exosome-depleted
FBS and horse serum were prepared by pelleting the
serum exosomes by ultracentrifugation at 100,000 × g
for 2 h at 4 °C, and the resulting supernatant was
filtered through a 0.2-μm pore filter. Cells were rou-
tinely maintained in a humidified chamber at 37 °C and
5 % CO2.
Patient-derived orthotopic xenograft plasma collection
PDX mice were produced and maintained as previously
described [15]. For terminal plasma collection the mice
were euthanized by CO2 asphyxiation and were placed
on their back (dorsal recumbence). The chest was
wetted with 70 % ethanol and the thoracic cavity was
exposed by an incision through the ribs. Blood was
collected with a 29G insulin syringe (Exel Int., 26028)
and dispensed into a microvette (EDTA) tube (SAR-
STEDT, Microvette 200K3E). Blood was mixed gently
in the tube to ensure exposure to EDTA-coated walls.
The plasma was separated by centrifuging the blood
sample at 2000 rcf for 15 minutes at room temperature.
The clear top layer was transferred to a labeled tube and
stored at -80 °C.
Patient plasma samples
Plasma samples were collected from women with no his-
tory of breast cancer (mean age = 42 years) and provided
by the Oklahoma Blood Institute, Oklahoma City, OK,
USA. Breast cancer plasma samples were collected from
women who were seen at the Stephenson Cancer Center
at the University of Oklahoma, Oklahoma City, OK
and underwent primary tumor biopsy or resection.
The University of Oklahoma Health Sciences Center
Human Research Participant Protection Institutional
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Review Board approved the study (#4381) and written
informed consent was obtained from all participants.
A total of 32 plasma samples was utilized: 16 healthy
plasma and 16 breast cancer plasma samples. Blood was
collected and dispensed into an EDTA collection tube
and mixed gently to ensure exposure to the EDTA-
coated walls. Plasma was separated by centrifugation on
a standard clinical centrifuge at 2000 rcf for 15 minutes
at room temperature. The clear top layer was transferred
to a labeled tube, and stored at -80 °C. Clinicopathologi-
cal factors and clinical stages were classified using the
tumor, node, metastasis (TNM) system (AJCC 7th edition).
All data for the breast cancer samples, including age,
tumor size, clinical stage, histological grade, hormone re-
ceptor, and human epidermal growth factor receptor 2
(HER2) amplification status, were obtained from the
clinical and pathological records.
Exosome isolation
Exosomes were isolated utilizing a combination of cen-
trifugation, ultracentrifugation, and filtration as we have
previously described [16], or with the Exoquick-TC re-
agent (System Biosciences, Mountain View, CA, USA)
following the manufacturer’s protocol. For ultracentrifu-
gation isolation, conditioned cell culture medium was
collected and centrifuged at 10,000 × g for 30 minutes at
4 °C, to remove cells and large debris. The supernatant
was filtered using a 0.22-μm pore filter and the exo-
somes were pelleted at 100,000 × g for 1 h at 4 °C. The
exosome pellet was washed with 10 ml of 1 × PBS and
pelleted again by centrifugation at 100,000 × g for 1 h at
4 °C. The resulting pellet was either suspended in 1 ×
PBS for whole exosome applications or further processed
for RNA or protein extraction. Plasma exosomes were iso-
lated using the Exoquick reagent (System Biosciences,
Mountain View, CA, USA) following the manufacturer’s
protocol. The resulting exosome pellet was suspended
in PBS and exosome concentration was estimated by
Bradford assay.
Western blot analysis
Total exosome protein was prepared by re-suspending
the exosomes in RIPA Buffer (50 mM Tris-HCl pH 7.4,
150 mM NaCl, 0.5 % sodium deoxycholate, 1 % NP-40,
and 0.1 % sodium dodecyl sulfate) containing 1 mM
phenlymethylsulfonyl fluoride, 5 μg/ml leupeptin, 2 μg/ml
aprotinin, and 1 μg/ml pepstatin A. About 30–40 μg of
protein from each sample was separated under non-
reducing conditions on a 10 % SDS-PAGE gel, transferred
to a polyvinylidene fluoride (PVDF) membrane, and blot-
ted with an antibody against CD63 (sc-5275, Santa Cruz
Biotechnology, Santa Cruz, CA, USA).
Electron microscopy and immunogold labeling
Whole exosomes suspended in 1 × PBS were fixed in 2 %
paraformaldehyde. The fixed sample was absorbed onto
formvar-coated copper grids for 20 minutes in a dry en-
vironment. Samples were then fixed in 1 % glutaralde-
hyde for 5 minutes. After being rinsed in distilled water,
samples were stained with uranyl oxalate for 5 minutes
followed by methyl cellulose uranyl acetate for 10 mi-
nutes on ice. Excess liquid was wicked off the grid using
filter paper, and grids were stored at room temperature
until imaging. For immunogold labeling, exosomes were
fixed in 2 % paraformaldehyde. Samples were absorbed
onto formvar-coated copper grids for 20 minutes in a
dry environment and washed with PBS three times.
Samples then underwent four washes in 50 mM glycine
followed by a 10-minute blocking step. Exosomes were
incubated with CD63 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) primary antibody for 30 minutes, and
then samples were washed in washing buffer six times.
Samples were incubated in secondary antibody conju-
gated to 10 nM gold particles for 20 minutes. Finally,
samples were washed in PBS, stabilized with glutaralde-
hyde, washed in water, and counterstained with uranyl
oxalate and methyl cellulose uranyl acetate. Imaging was
performed using a Hitachi H7600 microscope.
Nanoparticle tracking analysis
Isolated exosomes were diluted in PBS and analyzed using
the Nanosight NS300 System (Malvern Instruments, UK)
equipped with a blue laser (405 nm). Nanoparticles illu-
minated by the laser and their movement under Brown-
ian motion was captured for 60 seconds. Videos were
analyzed using the Nanosight Tracking Analysis (NTA)
software to provide particle concentrations and size distri-
bution profiles. Triplicate measurements were recorded
for each sample. Size distribution and concentration pro-
files were averaged across replicates to derive the repre-
sentative size distribution profiles.
RNA extraction
Total RNA was extracted from exosome pellet using the
TRIzol reagent (Invitrogen/Life Technologies) following
the manufacturer’s protocol. RNA concentration was quan-
titated using the NanoDrop ND-100 Spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA).
Small RNA library preparation and next generation
sequencing
Small RNA libraries were constructed using New England
Biolabs (NEB) NEBNext Multiplex Small RNA Library
Prep Set for Illumina sequencers and the NEB standard
protocol. Individual libraries were constructed using 1
μg of total RNA isolated from each sample. Each library
was indexed in order to multiplex four samples per
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sequencing run on the Illumina MiSeq platform using
MiSeq 50 cycle Reagent Kits v2. A minimum of 17 mil-
lion 50-bp sequencing reads were collected from each
sample and data were analyzed using Genesifter soft-
ware (formerly Geospiza) (PerkinElmer, Santa Clara,
CA, USA). Raw data for each sample were aligned to
the most recent mirBASE database (mirBase.org [17])
with remaining reads aligned to the most recent human
genome (hg18 build [18]) build in order to identify pre-
viously unknown regions that may encode for unique
miRNAs. Pairwise comparison of the alignment results
was done using Genesifter for identification of miRNAs
that are differentially expressed at a significant level,
i.e., upregulated or downregulated.
Quantitative real-time reverse transcription PCR
For microRNA expression analysis complementary DNA
from 10 ng of total RNA was synthesized by the addition
of a microRNA-specific 5X reverse transcription stem-
loop primer and the TaqMan microRNA Reverse Trans-
cription Kit, according to the manufacturer’s instructions.
Real-Time PCR was performed by diluting the comple-
mentary cDNA product in 2X TaqMan Universal Master
Mix II (with UNG) and 20X TaqMan microRNA Ex-
pression Assay for each mature microRNA to be mea-
sured: miR-21 (ID:000397), miR-122 (ID:002245), miR-451
(ID:001141) let-7a (ID:000377) and miR-1246 (custom
assay ID:CSQJA23). All reagents and primers were
from ThermoFisher/Life Technologies. The small ribo-
nuclear RNA RNU6B (ID:001093) served as a microRNA
expression normalization control for cellular microRNA
expression analysis.
Because no internal controls for exosome microRNA
analysis have been established, we used a synthetic
Caenorhabditis elegans miR-54 (cel-miR-54) RNA oligo-
nucleotide (Integrated DNA Technologies, Coralville, IA,
USA) as a spike-in control. Cel-miR-54 has previously
been shown not to affect human microRNA detection
[19]. The cel-miR-54 (0.25 nM) oligonucleotide was
spiked into each RNA sample prior to complementary
DNA synthesis and Real-Time PCR was performed using
the TaqMan microRNA assay (ID:001361, Life Technolo-
gies). PCR reactions were run in triplicate on the Bio-
Rad CFX 96 Real-Time PCR (Bio-Rad, Hercules, CA,
USA) instrument under the following conditions: hold at
95 °C for 10 minutes, then 40 cycles of 95 °C for 15 s
and 60 °C for 1 minute. A standard curve of cel-miR-54
was generated by five-fold serial dilution of cDNA. Ab-
solute expression values were determined by linear re-
gression analysis. Copy number values were computed
based on the equation:
microRNA copies = (ng cel-miR-54 × 6.022 × 1023)/
(24 nt × (1 × 109) × 650).
Immunoaffinity magnetic bead-based exosome isolation
Dynabeads Protein G (#10003D, ThermoFisher, Waltham,
MA, USA) were first prepared by binding 20 μg of CD63
primary antibody diluted in 1 × PBS with 0.02 % Tween-
20 to 100 μl of Dynabeads. Bead-antibody complex was
incubated with rotation for 10 minutes at room
temperature. To remove unbound antibody, the tube was
placed on a magnet and the supernatant was removed.
The antibody-coated beads were suspended in 400 μl of
1 × PBS with 0.02 % Tween-20. Exosome samples were
brought to a concentration of 50 μg in 200 μl in 1 ×
PBS with 0.1 % bovine serum albumin (isolation buffer).
Antibody-complexed beads (200 μl) were transferred to
a fresh 2.0-ml tube, washed with 500 μl of isolation buf-
fer, placed on a magnet, and the supernatant was dis-
carded. The tube was removed from the magnet and
the diluted exosome samples were added to the tube
containing the beads, mixed gently by pipetting, and in-
cubated overnight (18–22 h) at 4 °C, with gentle rota-
tion. After incubation, the tube was gently centrifuged
to collect the sample, placed on the magnet, and the
supernatant was removed and discarded. Bead-bound
exosomes were washed twice by adding 300–400 μl of
isolation buffer and mixed gently by pipetting; the tube
was then applied to the magnet for 1 minute and the
supernatant was discarded. RNA was extracted from
the exosome-bound beads following the manufacturer’s
protocol by directly applying TRIzol reagent to the
beads after the second wash.
Statistical analysis
Statistical analyses were completed using GraphPad
Prism software (GraphPad Software, Inc. La Jolla, CA,
USA). When appropriate Student’s t test was used to
determine statistically significant differences among con-
trol and experimental groups, with a p value <0.05 as
the level of significance. For each patient sample and
each microRNA analyzed, the average of three replicate
expression values was computed. Receiver operating
characteristic (ROC) curves were constructed using each
microRNA expression value individually or jointly. The
area under the curve (AUC) with 95 % CI was calculated
for each ROC curve. The Wilcoxon-Mann-Whitney test
was used to test the null hypothesis that the AUC is
equal to 0.5 (i.e., no predictive power).
Results
microRNAs are selectively enriched in exosomes secreted
from breast cancer cells
The mammary epithelial cell line MCF10A, and the
estrogen-receptor-positive (luminal subtype) MCF7 and
triple-negative (basal subtype) MDA-MB-231 breast can-
cer cell lines were plated at 5 × 106 in cell culture medium
supplemented with exosome-depleted serum for 3 days.
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Whole exosomes were isolated from the conditioned
medium, diluted in PBS and subjected to nanoparticle
tracking analysis (Fig. 1a). While the mean sizes of
MCF7 and MDA-MB-231 exosomes were comparable,
the MCF10A exosomes were slightly larger on average.
Next, we visualized the MCF7 and MDA-MB-231 iso-
lated exosomes by electron microscopy and found exo-
somes of the typical size and morphology (Fig. 1b). The
isolated exosomes had detectable CD63, an established
marker for exosomes, identified by immunogold labeling
(Fig. 1c) and by western blot analysis (Fig. 1d). These re-
sults indicate our capability of isolating and characterizing
human breast cancer exosomes.
To determine whether the microRNA profiles of
mammary epithelial cells and breast cancer cells may
differ, total RNA was isolated from the cells and exo-
somes and a small RNA library was prepared using
equal quantities of RNA. The resulting cDNA library
was sequenced and the reads were mapped onto the
human genome (complete RNA sequencing data is
available in Additional file 1). We first compared the
cellular microRNA content to the matched exosome
microRNAs for each cell line (Fig. 2). In MCF10A, 168
microRNAs were differentially expressed in the exosomes
compared to the cells, 33 of these microRNAs were higher
in the exosomes than the cells (selectively encapsulated by
exosomes), 9 of these were at least six-fold greater in the
exosomes versus the cell (Fig. 2a), and 11 of the selectively
secreted microRNAs were detected at a level of 1000 reads
or more (Fig. 2b). In MCF7, 196 microRNAs were differ-
entially expressed in the exosomes compared to the cells,
6 of them were at least 20-fold higher in the exosomes
versus the cell (Fig. 2c), and 4 of the 6 were detected at a
level of 200 reads or more (Fig. 2d). In MDA-MB-231,
101 microRNAs were differentially expressed in the exo-
somes compared to the cells, with 63 higher in the exo-
some versus the cell; 7 of these were at least six-fold
greater in the exosome versus the cell (Fig. 2e) and 10
were detected at a level of 1000 reads or more (Fig. 2f).
Interestingly, the top ranked microRNAs that are select-
ively encapsulated by exosomes differed among MCF7,
MDA-MB-231, and MCF10A cells (Fig. 2 and Table 1), in-
dicating different profiles of cancer exosome microRNAs
compared to normal epithelial exosome microRNAs.
Next, we asked whether any microRNAs are highly
present in breast cancer exosomes compared to mam-
mary epithelial exosomes. Our assumption was that
microRNAs highly enriched in breast cancer exosomes
over normal epithelial exosomes are potential circulating
biomarkers for breast cancer. Pairwise analysis showed
that 10 microRNAs were found at greater levels in MCF7
exosomes compared to MCF10A exosomes, whereas 132
Fig. 1 Characterization of exosomes from breast cancer cell lines. Exosomes were isolated from the conditioned media of MCF10A, MCF7, and
MDA-MB-231 cells. a Nanoparticle tracking analysis of 50X diluted MCF10A, MCF7 and MDA-MB-231 exosomes. b MCF7 and MDA-MB-231 exosomes
were visualized by electron microscopy (×30,000). c MCF7 and MDA-MB-231 exosomes were immunogold-labeled and visualized by electron microscopy
of human CD63-gold particles (10 nM gold) (right× 40,000; left× 100,000). d Western blot of CD63 (30–60 kDa) under non-reducing conditions
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Fig. 2 Small RNA next generation sequencing analysis of microRNAs in mammary epithelial cells and breast cancer cell lines versus exosomes.
Cellular and exosome RNA was isolated from normal mammary cells (MCF10A) and breast cancer cell lines (MCF7 and MDA-MB-231). microRNAs
were differentially expressed in MCF10A (a), MCF7 (c) and MDA-MB-231 (e) exosomes with a fold-change ≥6.0 (exosome vs. cell, p < 0.05) with
mapped reads ≥ 200 are plotted. The abundance of the microRNAs highly expressed in exosomes vs. the cellular RNA in MCF10A (b), MCF7 (d)
and MDA-MB-231 (f) are plotted by their mean number of reads per million reads
Table 1 microRNAs selectively secreted to exosomes from mammary epithelial cells and breast cancer cells
MCF10A MCF7 MDA-MB-231
microRNA Fold-change Mean reads microRNA Fold-change Mean reads microRNA Fold-change Mean reads
hsa-mir-4508 333.36 94.73 hsa-mir-3662 1136.26 375.59 hsa-mir-143 126.92 11.87
hsa-mir-320e 19.64 446.61 hsa-mir-122 227.25 751.19 hsa-mir-589 19.61 18.34
hsa-mir-320d-1 18.70 478.18 hsa-mir-1246 130.37 10773.97 hsa-mir-33a 16.15 15.10
hsa-mir-1246 16.73 1236.06 hsa-mir-142 105.21 34.78 hsa-mir-29a 9.46 44.22
hsa-mir-320c-1 16.67 1231.55 hsa-mir-1290 105.21 34.78 hsa-mir-1246 8.61 2181.03
hsa-mir-4516 12.17 103.76 hsa-mir-451 20.34 201.71 hsa-mir-324 8.46 23.73
hsa-mir-193a 8.33 94.73 hsa-mir-16-1 6.11 3398.83
hsa-mir-320b-1 6.70 6148.72
hsa-mir-92b 6.07 3848.03
The microRNAs with a fold-change ≥6.0 in the exosome vs. the cellular content and mapped reads ≥30 are shown. The fold-change was calculated by normalizing
the reads to the number of mapped reads. microRNAs in bold were further evaluated in this study
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microRNAs were found at greater levels in MDA-MB-231
exosomes compared to MCF10A exosomes. We listed the
top 8–10 of these microRNAs in MCF7 and MDA-MB-
231 cells, considering their absolute abundance in the exo-
somes (Table 2). As shown in Table 2, miR-1246 was most
enriched, followed by miR-122 in MCF7 exosomes, and
miR-21 was most enriched in MDA-MB-231 cells, followed
by let-7a. These microRNA species, along with others
shown in Table 2 were considered potential exosome
microRNAs that may serve as biomarkers for breast
cancer.
We then selected several microRNAs that are select-
ively secreted or highly abundant in the breast cancer
MCF7 exosomes (miR-1246, miR-451, and miR-122) for
validation by real-time PCR analysis in seven breast can-
cer cell lines representing the various breast cancer sub-
types (Fig. 3). The data indicated that these microRNA
species are selectively secreted and enriched in breast
cancer exosomes relative to their cellular content and
compared to mammary epithelial exosomes, with a few
exceptions (miR-1246 in T47D and miR-451 in BT-474).
Based on their fold-change, the enrichment of all three
microRNAs seemed to be more pronounced in the es-
trogen receptor (ER)+, progesterone receptor (PR)+ cell
line-derived exosomes (MCF7, ZR-75-1), and the ER-,
PR-, HER2- cell-line-derived exosomes (MDA-MB-213
and BT-20). These observations are consistent with the
RNA sequencing results.
miR-1246 is detected at significantly higher levels in the
plasma exosomes of patient-derived orthotopic xenograft
(PDX) mice compared to control mice
We reasoned that mice bearing human breast tumors
should have circulating human exosomes and sought to
determine whether selectively secreted human exosome
microRNAs are detectable in the plasma of these mice.
Plasma was collected from nine Huntsman Cancer
Institute-PDX (HCI-PDX) mice models [20] and three
non-tumor-bearing nod-scid gamma (NSG) mice at the
time of killing (see PDX information in Additional file 2).
Whole exosomes were isolated from the plasma of a
PDX mouse and analyzed by nanoparticle tracking ana-
lysis (Fig. 4a). The exosomes were further purified by
magnetic-bead-based immunoaffinity isolation using an
antibody against human CD63. Total RNA was extracted
from the bead-bound exosomes and the expression of
miR-1246, miR-451 and miR-122 were measured by
qRT-PCR.
As shown in Fig. 4b, both miR-122 and miR-1246 were
detected in the human-CD63-positive exosome popula-
tion from the PDX mice, with miR-1246 levels being
significantly higher (p < 0.001) in PDX mouse plasma
compared to the NSG control plasma. miR-451 was not
detectable in either the PDX mouse plasma or the NSG
plasma. While the expression of plasma exosome miR-
1246 was higher in mice with any subtypes of breast
cancer, those mice with ER- and PR- tumors had the
highest levels (Fig. 4c). These data suggest that breast
cancer exosomes are released to the circulation in hu-
man breast cancer PDX mouse models and that human-
exosome-specific microRNAs can be detected in the
mouse plasma.
miR-1246 and miR-21 are highly expressed in plasma
exosomes from patients with breast cancer
To determine whether enriched exosome microRNAs
could be detected in circulating exosomes from breast can-
cer patients we collected 16 plasma samples from women
with no history of breast cancer and 16 plasma samples
from women with breast cancer (mostly ER+, grade 2–3;
Table 2 microRNAs in breast cancer cell line exosomes compared to mammary epithelial cell exosomes










hsa-mir-1246 1236.06 10773.97 8.72 0.00E + 00 hsa-mir-21 9527.59 157280.08 16.51 1.00E-20
hsa-mir-122 18.04 751.19 41.63 0.00E + 00 hsa-let-7a-1 1470.64 30328.39 20.62 1.00E-20
hsa-mir-3662 0.45 375.59 832.59 0.00E + 00 hsa-let-7f-1 1163.88 29759.95 25.57 1.00E-20
hsa-mir-451 22.56 201.71 8.94 2.99E-10 hsa-let-7e 744.34 12747.48 17.13 1.00E-20
hsa-mir-200a 0.45 86.94 192.73 9.02E-08 hsa-mir-30e 789.45 12061.46 15.28 1.00E-20
hsa-mir-203 4.51 45.21 10.02 2.27E-03 hsa-mir-146a 76.69 11607.35 151.35 1.00E-20
hsa-mir-142 0.45 34.78 77.09 7.23E-04 hsa-let-7i 2133.78 11003.31 5.16 1.00E-20
hsa-mir-1290 0.45 34.78 77.09 7.23E-04 hsa-let-7 g 387.96 8518.10 21.96 1.00E-20
hsa-mir-29a 360.89 6881.79 19.07 1.00E-20
hsa-mir-29c 288.71 5744.89 19.9 1.00E-20
The microRNAs with a fold-change ≥5.0 in each comparison and mapped reads ≥30 for MCF7 and ≥5000 for MDA-MB-231 are shown. The fold-change was calculated
by normalizing the reads to the number of mapped reads. The P value was calculated using the likelihood ratio test. microRNAs in bold were further evaluated in
this study
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see Table 3 for patient sample information). Plasma exo-
somes were isolated and verified by electron microscopy
(Fig. 5a). Total RNA was isolated from the whole exosome
population and the expression of several selectively se-
creted microRNAs (cell to the exosome) and/or abun-
dantly expressed (cancer exosomes versus the MCF10A
exosomes) (miR-1246, miR-21, miR-122, and let-7a) was
analyzed by real-time PCR. As shown in Fig. 5, the expres-
sion of plasma exosome miR-1246 (p = 0.03) and miR-21
(p = 0.04) was significantly higher in the group of patients
with breast cancer as compared to the normal population
(Fig. 5b). There was no significant correlation with patient
clinicopathological characteristics such as tumor stage,
grade, or size, likely due to the limited sample size
(Additional file 3).
ROC curves were constructed separately for miR-21
(Fig. 6a) and miR-1246 (Fig. 6b), and combined (Fig. 6c)
to compare the diagnostic value of miR-1246 and miR-
21 to predict breast cancer. The AUC for miR-21 was
0.69 (95 % CI 0.50, 0.88; p = 0.048) and for miR-1246
was 0.69 (95 % CI 0.49, 0.89; p = 0.068), indicating fair
predictive power. When miR-1246 and miR-21 were
combined, the AUC increased to 0.73 (95 % CI 0.53,
0.92; p = 0.022). These data indicate that breast cancer
exosome microRNAs can be detected in the circulation
in patients with breast cancer, and that their expression
could differentiate patients with breast cancer from
healthy control subjects.
Discussion
The most interesting finding of the present study was
that breast cancer exosome microRNAs possess unique
signatures of the malignancy, and could serve as circu-
lating biomarkers for breast cancer. Circulating micro-
RNAs have been proposed as biomarkers that may aid in
cancer diagnosis and prognosis, and for treatment moni-
toring. Indeed, many studies have evaluated this possibil-
ity, yet very few have reported consistent results [21].
Our current understanding of circulating microRNAs is
that there are distinct populations of microRNAs either
within membrane-bound vesicles or associated with pro-
tein complexes, which may likely originate from different
cell types and reflect different release mechanisms [22].
This suggests that plasma exosome purification strategies
may serve to enrich those microRNAs that originate from
certain cell types.
Fig. 3 qRT-PCR analysis of microRNAs in breast cancer cell line
exosomes versus mammary epithelial cell exosomes. qRT-PCR analysis
of selected microRNAs that are abundantly present in MCF7, ZR-75-1,
T47D, MDA-MB-231, BT-20, BT-474, and SK-BR-3 exosomes vs. MCF10A
exosomes. Fold-change in expression is shown for the exosome
microRNAs relative to their cellular microRNA levels and normalized to
the spike-in cel-miR-54 control
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In this study, we focused our efforts on cancer exo-
somes as specific carriers of microRNAs in order to
more specifically analyze circulating cancer microRNAs.
This is in contrast to many published biomarker studies
in the field of breast cancer research, where efforts are
usually focused solely on profiling circulating micro-
RNAs in patients with breast cancer [23, 24]. We began
this study by characterizing breast cancer exosome
microRNA signatures using cell line-derived exosomes.
Genome-wide profiling of the microRNA content of
breast cancer cell line exosomes revealed that certain
microRNAs are selectively enriched in cancer exosomes vs.
exosomes from normal epithelial cells. This phenomenon
provides us with a rich resource for biomarker discovery.
PDX mouse models were then applied to verify our
findings from cell lines, and one of the microRNAs
identified in cell line studies, miR-1246, was abundant,
and its level was significantly higher in the plasma
exosomes from the PDX mice compared to the control
mice. This observation supports the concept that breast
cancer exosome microRNAs are released from the pri-
mary tumor site and are detectable in the circulation.
We then extended our efforts to patient plasma samples
to determine whether the candidate exosome microRNAs
are associated with the presence of a breast tumor. Based
on the selective enrichment and absolute abundance, we
identified miR-1246, miR-122, miR-21, and let-7a as can-
didate exosome microRNAs that may serve as biomarkers
indicative of breast cancer. The confirmation that miR-
1246 and miR-21 levels are significantly higher in plasma
exosomes from patients with breast cancer vs. those from
normal control subjects indicates that circulating breast
cancer exosome microRNAs are promising biomarkers for
this malignancy.
The fairly consistent results from cell line exosome
characterization to plasma exosome microRNA detection
Fig. 4 Characterization and microRNA expression analysis of human exosomes isolated from the plasma of patient-derived xenograft (PDX) mice.
Exosomes were isolated from the plasma of Huntsman Cancer Institute human breast cancer orthotopic xenograft (HCI-PDX) and nod scid
gamma (NSG) mice. a Exosomes were characterized by nanoparticle tracking analysis of 500X diluted exosomes (n = 3). b-c Exosomes were isolated
from the mouse plasma exosome sample by magnetic-bead based immunoaffinity isolation using an antibody against human CD63, the total RNA
was extracted and the expression of miR-1246 and miR-122 were evaluated by qRT-PCR analysis (absolute quantitation) in the immunoaffinity isolated
human CD63-positive exosomes from the plasma of three NSG (n = 3, in triplicate) and nine HCI-PDX models (with available biological replicates as
indicated in c, in triplicate); Student’s t test; ***p < 0.001. The corresponding clinical biomarkers including the estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor 2 (HER2) amplification status and the PAM50 subtype of the human tumor (if known) are indicated
and are available in Additional file 2
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in PDX mice and breast cancer patients are in agreement
with a recent massive genomic and proteomic study indi-
cating that breast cancer cell lines are reasonable models
for analyzing context-dependent gene expression, includ-
ing microRNA expression [25]. While direct profiling of
circulating exosome microRNAs has been a common ap-
proach for cancer biomarker identification, the challenge
to this approach is that the exosomes found in the cir-
culation are a heterogeneous mixture of exosomes from
various other cells and tissues, which compromises the
specificity of the identified microRNA signatures. Our
results indicate that deriving information from a cell
line study and confirming the observation through investi-
gations in mice and humans seems to be a valid alternative
approach for development of circulating biomarkers.
Our finding that the levels of the selectively secreted
and highly enriched exosome miR-1246 were signifi-
cantly higher in the plasma of PDX mice vs. the NSG
control mice indicates that the PDX mouse model is
suitable for a breast cancer biomarker study. The PDX
mouse model has recently been extensively used for
breast cancer research due to its suitability in recapitu-
lating the heterogeneity and behavior of the original
tumor. However, most studies with PDX mice have been
focused on verifying breast cancer biology and screening
of therapeutic agents to provide evidence to facilitate
personalized medicine [26, 27]. To our knowledge, the
PDX mouse model has never been applied for investi-
gating plasma exosome microRNAs as biomarkers for
breast cancer. Considering that breast cancer PDX
mouse models are well-established [20], the use of
these mouse models for a biomarker study is rather ap-
pealing. The advantages of using a PDX mouse model
to evaluate circulating exosome microRNAs as bio-
markers for breast cancer may include first, the use of a
cross-species model (human and mouse) that renders
an opportunity to specifically enrich human cancer exo-
somes from the mouse plasma and more specific detec-
tion of cancer exosome microRNAs in the circulation;
second, the variety of tumors that may be grown, includ-
ing well-established subtypes of human breast cancer in
PDX mice, provides a unique platform to evaluate cancer
exosome microRNAs across subtypes; and last, the possi-
bility to analyze circulating human exosome microRNAs
at various stages of tumor growth and progression, which
could help to determine whether plasma exosome micro-
RNAs can serve as biomarkers for early detection. Further
exploration of the PDX mouse model for the study of
cancer biomarkers is warranted.
We have detected plasma exosome miR-21 and miR-
1246 at significantly higher levels in patients with breast
cancer vs. healthy women. Based on previous reports,
both miR-21 and miR-1246 are cancer-associated micro-
RNA species. miR-21 is considered an oncogenic micro-
RNA that is known to be overexpressed in both male
and female invasive breast cancer relative to normal
breast tissue [4, 5, 28]. This over-expression positively
correlates to the size, stage, grade and proliferation rate
of the tumor, and is associated with metastatic breast
cancer [29, 30]. Differential expression of serum miR-21
has been previously identified in circulating exosomes
from patients with lung cancer [31], melanoma [32], and
breast cancer [33] with limited diagnostic value.
Compared to miR-21, miR-1246 is relatively less investi-
gated in cancer but was previously identified as selectively
released from breast cancer cells [14], and has been found
at greater levels in serum from patients with breast cancer
compared to their matched tumor tissues [34]. Further-
more, a most recent study indicated that serum miR-1246
is elevated among patients with invasive breast cancer
[35]; these observations are consistent with our current
findings. In addition, miR-1246 has also been found to be
elevated in serum from patients with esophageal cancer
[36], colon cancer [37], and pancreatic cancer [38]. Thus,
our observation that the levels of plasma exosome miR-21
and miR-1246 are significantly higher in patients with
breast cancer is in line with previous reports and suggests
that these two exosome microRNA species are selectively
enriched and significantly elevated in plasma exosomes
Table 3 Clinicopathological features of patients with breast
cancer included in the study
Plasma sample Age ER status PR status HER2 status Grade Stagea
PL7 48 - + - 3 NA
PL8 67 + + - 2 IIA
PL9 56 + - - 2 NA
PL10 56 + + - 3 IIB
PL11 63 + + - 1 IA
PL12 53 + + - 3 NA
PL13 51 NA NA NA 3 IIIA
PL14 52 - - + 0
PL15 71 + + - 2/1 IA
PL16 80 + + - 2 IIA
PL17 75 + - + NA
PL18 51 + + - 1 IIA
PL19 68 + + - 3 IIB
PL20 56 + + + 2 NA
PL21 65 + + - 2 NA
PL22 42 + + - 2 IIA
Mean age 59.6
Median age 56.0
aPathologic TNM tumor staging, (American Joint Committee on Cancer Care
7th Edition). ER estrogen receptor, PR progesterone receptor, HER2 human
epidermal growth factor receptor 2 amplification, NA not available
Hannafon et al. Breast Cancer Research  (2016) 18:90 Page 10 of 14
potentially among a spectrum of different types of human
cancer. While these microRNAs may not themselves be
strong predictors of breast cancer alone, they may serve as
a companion tools following other screening procedures
such as individual breast cancer risk assessment and
mammography.
It is important to note that recent studies have evalu-
ated exosome microRNA expression and their associ-
ation with cancer, including those of the prostate [39],
lung [40], ovary [11], liver [41], colorectal [42], skin [32],
pancreas [38], and glioblastoma [43]. Furthermore, a
recent study evaluated the levels of previously identi-
fied circulating microRNAs (miR-373, miR-101 and
miR-372) in cell-free versus extracellular vesicle prepa-
rations from the serum of patients with breast cancer
[44]. However, to date, no study has fully characterized
the exosome microRNA content of breast cancer cells
and examined the levels of microRNAs in circulating
exosomes from the plasma of human-tumor bearing
mice and patients with breast cancer as biomarkers
for breast cancer, thus making this study novel and
unique.
Given the magnitude of breast cancer incidence and
the lack of sensitive and specific biomarkers for early
detection of this malignancy [2, 3], the results from this
study support further investigations of the potential of
Fig. 5 qRT-PCR analysis of exosome microRNA expression in normal plasma and plasma from patients with breast cancer. Plasma samples were
collected under an Institutional Review Board approved protocol from healthy women with no history of cancer (n = 16, mean age 42 years,
age range 27–66) and women with breast cancer (n = 16, mean age 59.6 years, range 42–80; see Table 3). Exosomes were isolated from plasma
samples using the Exoquick reagent and total RNA was extracted. a Human plasma exosomes were visualized by electron microscopy (×30,000).
b Candidate microRNA expression was measured in normal plasma (n = 16) and plasma from patients with breast cancer (n = 16) by qRT-PCR.
Student’s t test, *p < 0.05
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exosome microRNAs as effective biomarkers for breast
cancer. Whereas most of the studies mentioned above,
including the current study, identified exosome micro-
RNA species that are significantly elevated in the circu-
lation in patients with cancer, the sensitivity and
specificity of these exosome microRNAs are not yet sat-
isfactory. This indicates that plasma exosome popula-
tions are heterogeneous and may be derived from all
types of cells, especially blood cells. In this context,
while current circulating exosome microRNA detection
may not be superior to circulating microRNA analysis,
in terms of the sensitivity and specificity for detecting
cancer, it does point out an important new direction by
which specific and sensitive plasma biomarkers can be
developed. Therefore, methods to selectively isolate
cancer exosomes from the circulation becomes a key
step in the future development of exosome biomarkers
for breast cancer.
Conclusion
In conclusion, we have demonstrated that certain micro-
RNA species, such as miR-21 and miR-1246, are select-
ively enriched in human breast cancer exosomes,
detectable in plasma from breast cancer PDX mice, and
significantly elevated in plasma from patients with breast
cancer. Our results support the notion that circulating
exosome microRNA profiles can serve as an important
companion diagnostic tool for breast cancer. Further
studies are required to specifically isolate cancer exo-
somes from patient plasma and establish exosome
microRNA signatures indicative of breast cancer.
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